In this interview, we are pleased to welcome Ivan Kairatov, a Biopharma expert with deep knowledge of tech and innovation in the industry and extensive experience in research and development, particularly in gene therapy for sensory disorders. Today, Ivan will share insights on the recent positive
Ivan Kairatov is a Biopharma expert, with profound knowledge in technology and innovation in the medical industry, and extensive experience in research and development. Today, we'll delve into a study from the University of Colorado Anschutz Medical Campus, discussing its significance for diabetes
Key players in the pharmaceutical landscape, Summit Therapeutics and Pfizer, are embarking on a noteworthy collaboration to test out Summit’s experimental immunotherapy, ivonescimab, combined with Pfizer’s sophisticated antibody-drug conjugates (ADCs) in upcoming clinical trials targeting specific
Ivan Kairatov is a Biopharma expert, with deep knowledge of tech and innovation in the industry and experience in research and development. Can you tell us a little about your professional background and your role as a biopharma expert? Certainly. I have spent the last couple of decades working at
In a groundbreaking advancement, researchers from Tsinghua University and Beijing Tsinghua Changgung Hospital have developed a new approach called ECG-LM (Electrocardiogram-Large Model) that significantly enhances the interpretation of electrocardiogram (ECG) data for diagnosing heart diseases.
Cancer therapy has always been a challenging field, with the need to balance efficacy and minimize side effects. Traditional treatments often lack precision, leading to systemic toxicity and reduced patient quality of life. In recent years, the development of drug-based nanostructures has emerged
The biopharmaceutical industry is undergoing rapid transformation due to the rising popularity of cell and gene therapy for various cancer conditions, some uncommon diseases, and degenerative conditions, as traditional drugs and biological products show limited success. The field is now moving to
The global lung cancer surgery market is on the cusp of transformative growth, driven by several crucial factors from 2025 to 2035. Lung cancer remains the leading cause of cancer-related deaths worldwide, with over 1.8 million recorded fatalities in 2020 alone. Surgical interventions such as
The telehealth and telecare industries are experiencing unprecedented transformations driven by shifts in leadership, rapid technological advancements, and ongoing legal challenges. These elements are collectively redefining the landscape of healthcare delivery, compelling companies to adapt and
AI is revolutionizing precision and personalized oncology care by enabling more accurate diagnoses, predicting patient outcomes, and tailoring treatments to individual needs. Through advanced algorithms and machine learning, AI can analyze vast amounts of data, including medical records, genetic
